Document is current
Any future updates will be listed below
-
Authors
Bank, Ute
Deiser, Katrin
Plaza-Sirvent, Carlos
Osbelt, Lisa
Witte, Amelie
Knop, Laura
Labrenz, Rebecca https://orcid.org/0000-0003-0119-6386
Jänsch, Robert
Richter, Felix
Biswas, Aindrila
Zenclussen, Ana C.
Vivier, Eric https://orcid.org/0000-0001-7022-8287
Romagnani, Chiara https://orcid.org/0000-0002-5167-7463
Kühl, Anja A.
Dunay, Ildiko R.
Strowig, Till https://orcid.org/0000-0003-0185-1459
Schmitz, Ingo https://orcid.org/0000-0002-5360-0419
Schüler, Thomas https://orcid.org/0000-0002-0567-4827
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (DFG priority program 1937 (project SCHU 2326/2-1))
- License Information
-
More Information
Article History
Received: 9 April 2018
Accepted: 24 January 2020
First Online: 26 February 2020
Competing interests
: The authors declare competing financial interests. The E.V. laboratory is supported by the European Research Council (ERC) under the “European Union’s Horizon 2020 research and innovation program (Grant agreement no. 694502)”, Agence Nationale de la Recherche, Innate Pharma, MSDAvenir, Ligue Nationale contre le Cancer (Equipe labelisée “La Ligue”) and Marseille-Immunopole. E.V. is cofounder, shareholder, and employee of Innate Pharma.
